YI Quote, Financials, Valuation and Earnings

CASI Pharmaceuticals has a net margin of -0.5% compared to 111's net margin of -172.28%. 111's return on equity of -21.52% beat CASI Pharmaceuticals's return on equity of -630.22%.

111 has a consensus price target of --, signalling upside risk potential of 691.06%. On the other hand CASI Pharmaceuticals has an analysts' consensus of $4.00 which suggests that it could grow by 217.46%. Given that 111 has higher upside potential than CASI Pharmaceuticals, analysts believe 111 is more attractive than CASI Pharmaceuticals.

111 has a beta of 0.442, which suggesting that the stock is 55.797% less volatile than S&P 500. In comparison CASI Pharmaceuticals has a beta of 0.530, suggesting its less volatile than the S&P 500 by 47.038%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. CASI Pharmaceuticals pays out -- of its earnings as a dividend.

111 quarterly revenues are $485.1M, which are larger than CASI Pharmaceuticals quarterly revenues of $6.2M. 111's net income of -$2.4M is higher than CASI Pharmaceuticals's net income of -$10.8M. Notably, 111's price-to-earnings ratio is -- while CASI Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 0.64x for CASI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

China Pharma Holding has a net margin of -0.5% compared to 111's net margin of -69.14%. 111's return on equity of -21.52% beat China Pharma Holding's return on equity of -61.79%.

111 has a consensus price target of --, signalling upside risk potential of 691.06%. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that 111 has higher upside potential than China Pharma Holding, analysts believe 111 is more attractive than China Pharma Holding.

111 has a beta of 0.442, which suggesting that the stock is 55.797% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.789, suggesting its less volatile than the S&P 500 by 21.096%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

111 quarterly revenues are $485.1M, which are larger than China Pharma Holding quarterly revenues of $1.1M. 111's net income of -$2.4M is lower than China Pharma Holding's net income of -$785.6K. Notably, 111's price-to-earnings ratio is -- while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 0.93x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -0.5% compared to 111's net margin of --. 111's return on equity of -21.52% beat Sinovac Biotech's return on equity of -1.05%.

111 has a consensus price target of --, signalling upside risk potential of 691.06%. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that 111 has higher upside potential than Sinovac Biotech, analysts believe 111 is more attractive than Sinovac Biotech.

111 has a beta of 0.442, which suggesting that the stock is 55.797% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. 111 pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

111 quarterly revenues are $485.1M, which are larger than Sinovac Biotech quarterly revenues of --. 111's net income of -$2.4M is higher than Sinovac Biotech's net income of --. Notably, 111's price-to-earnings ratio is -- while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 1.49x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -0.5% compared to 111's net margin of -45.49%. 111's return on equity of -21.52% beat Zai Lab's return on equity of -33.29%.

111 has a consensus price target of --, signalling upside risk potential of 691.06%. On the other hand Zai Lab has an analysts' consensus of $56.38 which suggests that it could grow by 67.96%. Given that 111 has higher upside potential than Zai Lab, analysts believe 111 is more attractive than Zai Lab.

111 has a beta of 0.442, which suggesting that the stock is 55.797% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.125%.

111 has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111 pays -- of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

111 quarterly revenues are $485.1M, which are larger than Zai Lab quarterly revenues of $106.5M. 111's net income of -$2.4M is higher than Zai Lab's net income of -$48.4M. Notably, 111's price-to-earnings ratio is -- while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111 is 0.03x versus 8.16x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.